# Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

> **NCT03911973** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kari Wisinski** · enrollment: 37 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Gedatolisib
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03911973
- **Lead sponsor:** Kari Wisinski
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-17
- **Primary completion:** 2024-07
- **Final completion:** 2024-07
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911973, "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT03911973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*